NEW HAVEN, Conn., April 3 /PRNewswire/ -- Achillion Pharmaceuticals, Inc., announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be sold by Achillion.
Cowen & Co., LLC will be acting as the sole book-running manager, CIBC World Markets Corp. will act as co-lead manager and JMP Securities LLC will be co-manager. The number of shares to be offered and the price range for the offering have not yet been determined. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for the offering may be obtained, when available, from Cowen & Co., LLC, Prospectus Department at ADP, 1155 Long Island Avenue, Edgewood, NY 11717, (631) 254-7106.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Achillion
Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. The Company's discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is currently developing treatments for HIV infection, chronic hepatitis C infection and serious hospital-based bacterial infections.
Mary Kay Fenton
Achillion Pharmaceuticals, Inc.
Tel. (203) 624-7000
Achillion Pharmaceuticals, Inc.CONTACT: Mary Kay Fenton of Achillion Pharmaceuticals, Inc.,+1-203-624-7000
